Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus HEXALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus HEXALEN.
CYTOXAN (LYOPHILIZED) vs HEXALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. It also has immunosuppressive effects by suppressing B and T lymphocyte function.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
500-1000 mg/m² IV every 2-4 weeks, or 60-120 mg/m² IV daily for 2-3 days, or 500-750 mg/m² IV every 3 weeks. Oral: 50-200 mg daily as continuous therapy.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
None Documented
None Documented
Cyclophosphamide: 4-8 hours (dose-dependent, prolonged in hepatic impairment). Active metabolites (e.g., phosphoramide mustard): 6-12 hours.
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Renal: 30-60% of unchanged drug and metabolites (primarily phosphoramide mustard and acrolein). Biliary/fecal: minor (<10%).
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Category C
Category C
Alkylating Agent
Alkylating Agent